The Impact of Cyclic Glycine-Proline on Alzheimer's Disease Progression

This diagram was made using Edrawmax. The poster presented by Paulina Panasiuk from the Molecular Biotechnology Department of Jagiellonian University, investigates the therapeutic effects of Cyclic Glycine-Proline (cGP) on Alzheimer's disease (AD) mice models. The abstract summarizes the study's objective: exploring cGP's potential in mitigating memory deficits and reducing amyloid plaque accumulation, hallmarks of Alzheimer's pathology. Through experiments using the APP/PS1 transgenic mouse model, it shows that cGP treatment significantly improves spatial memory performance and reduces amyloid plaque burden, indicating cGP's potential as a candidate for AD treatment. The results section includes bar graphs and Morris water maze tests, illustrating improved memory function and navigation efficiency in cGP-treated mice compared to untreated ones. The findings suggest cGP as a promising substance for AD interventions, with the visual data supporting the textual conclusions.